^
Association details:
| Biomarker: | HER-2 underexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | DAN-311 (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract P2-13-09: An investigational next generation ADC (DAN-311) is highly effective in HER2-low breast cancer models
Published date:
02/15/2022
Excerpt:
We also report the enhanced efficacy of DAN-311 in a HER2-low breast cancer (JIMT-1) xenograft mouse model….DAN-311 exhibited significantly greater tumor growth inhibition compared to vehicle, core particle, and trastuzumab….DAN-311, a Next-Generation ADC with a HER2-targeting agent (trastuzumab) on a polymeric nanoparticle conjugated with CPT demonstrated a significant ability to inhibit tumor growth in a HER2-low xenograft mouse model.
DOI:
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-09
